poisar

Stocks · News reference

Nurix Therapeutics to Present New Data on Bexobrutideg at 68th ASH Annual Meeting

Fiscal.ai

Nurix Therapeutics announced it will present updated clinical data from its Phase 1a/1b trial of bexobrutideg (NX-5948) for the treatment of relapsed/refractory CLL/SLL.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading